Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA
- PMID: 16859543
- PMCID: PMC1550719
- DOI: 10.1186/1476-7961-4-11
Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA
Abstract
Background: Aspergillus fumigatus, a widely distributed fungus, has been implicated in causing life threatening infections as well as severe asthma and allergic diseases in man. Allergic affliction like allergic bronchopulmonary aspergillosis (ABPA) is a disabling lung disease frequently seen in patients with asthma and cystic fibrosis. Immunodiagnosis of the former is comparatively easier due to the availability of purified antigens and sensitive methods. However, this is not true with cystic fibrosis patients where the prevalence of ABPA is fairly high and the morbidity and mortality are significant.
Methods: In the present study, we have evaluated purified recombinant allergens from A. fumigatus, namely Asp f 1, f 2, f 3, f 4, and f 6 using ELISA and a semi-automated method (ImmunoCAP). We studied 17 patients each from cystic fibrosis with ABPA, and cystic fibrosis with asthma, 22 cystic fibrosis with no ABPA or asthma, and 11 age matched controls.
Results: The results indicate that no antigen, antibody or method is capable of differentiating cystic fibrosis (CF) with ABPA from other CF patients, although some allergens showed strong reaction or showed more prevalence among the patients studied.
Conclusion: When results of several allergens such as Asp f 1, f 2, f 3, f 4, and f 6 in their binding to IgA, IgG, and IgE antibodies were analyzed, a more strong discrimination of CF patients with ABPA was possible from the other groups studied.
Figures




Similar articles
-
IgE antibody to Aspergillus fumigatus recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis.Allergy. 2004 Feb;59(2):198-203. doi: 10.1046/j.1398-9995.2003.00310.x. Allergy. 2004. PMID: 14763934
-
Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy.Eur J Immunol. 1998 Apr;28(4):1155-60. doi: 10.1002/(SICI)1521-4141(199804)28:04<1155::AID-IMMU1155>3.0.CO;2-6. Eur J Immunol. 1998. PMID: 9565354
-
Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA.Clin Exp Allergy. 2000 Jul;30(7):988-93. doi: 10.1046/j.1365-2222.2000.00837.x. Clin Exp Allergy. 2000. PMID: 10848921
-
Serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis: State of the art and further challenges.Med Mycol. 2010 Nov;48 Suppl 1:S77-87. doi: 10.3109/13693786.2010.514301. Med Mycol. 2010. PMID: 21067334 Review.
-
Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.Ann Thorac Med. 2017 Apr-Jun;12(2):74-82. doi: 10.4103/atm.ATM_231_16. Ann Thorac Med. 2017. PMID: 28469716 Free PMC article. Review.
Cited by
-
Proteomics as a Tool to Identify New Targets Against Aspergillus and Scedosporium in the Context of Cystic Fibrosis.Mycopathologia. 2018 Feb;183(1):273-289. doi: 10.1007/s11046-017-0139-3. Epub 2017 May 8. Mycopathologia. 2018. PMID: 28484941 Review.
-
Allergic Bronchopulmonary Aspergillosis.J Fungi (Basel). 2016 Jun 6;2(2):17. doi: 10.3390/jof2020017. J Fungi (Basel). 2016. PMID: 29376934 Free PMC article. Review.
-
Aspergillus in Children and Young People with Cystic Fibrosis: A Narrative Review.J Fungi (Basel). 2025 Mar 9;11(3):210. doi: 10.3390/jof11030210. J Fungi (Basel). 2025. PMID: 40137248 Free PMC article. Review.
-
Sensitisation to recombinant Aspergillus fumigatus allergens and clinical outcomes in COPD.Eur Respir J. 2023 Jan 6;61(1):2200507. doi: 10.1183/13993003.00507-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 35926878 Free PMC article.
-
New Commercially Available IgG Kits and Time-Resolved Fluorometric IgE Assay for Diagnosis of Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis.Clin Vaccine Immunol. 2015 Dec 23;23(3):196-203. doi: 10.1128/CVI.00498-15. Clin Vaccine Immunol. 2015. PMID: 26698651 Free PMC article.
References
-
- Greenberger PA. Allergic bronchopulmonary aspergillosis. In: Adkinson NF, Jr, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER, editor. Middleton's Allergy, Principles and Practices. 2. Philadelphia: Mosby; 2003. pp. 1353–1371.
-
- Kurup VP, Apter AJ. Immunology and Allergy Clinics of North America. Philadelphia: WB Saunders Company; 1998.
-
- Stevens DA, Moss R, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, Skov M, Maish W, Mastella G, participants in the Cystic Fibrosis Foundation Consensus Conference Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic fibrosis foundation consensus conference. Clin Infect Dis. 2003;37:S225–S264. doi: 10.1086/376525. - DOI - PubMed
-
- Greenberger PA. Diagnosis and management of allergic bronchopulmonary aspergillosis. Allergy Proc. 1994;15:335–339. - PubMed
-
- Becker JW, Burke W, McDonald G, Greenberger PA, Henderson WR, Atiken ML. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest. 1996;109:1536–1540. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous